For the better part of two decades, finasteride has been the gold standard for treating androgenetic alopecia in men. It works. But it also comes with a disclaimer that makes a lot of people hesitate: potential sexual side effects, mood changes, and a small but vocal group of users reporting persistent symptoms even after discontinuation. Women largely can’t use it at all, at least not orally, due to teratogenicity concerns. Topical spironolactone exists as an alternative, but its evidence base for hair growth is thin compared to finasteride’s extensive clinical track record.
Enter clascoterone, a topical androgen receptor antagonist that works differently from anything currently on the hair loss market. If you haven’t heard of it yet, you’re not alone. The molecule was originally developed for acne under the brand name Winlevi and received FDA approval for that indication in 2020. But researchers always suspected it might have applications for pattern hair loss too, since both conditions are driven by the same underlying hormone: dihydrotestosterone, or DHT.
How Clascoterone Works (and Why That Matters)
To understand why clascoterone represents a genuinely new approach, you need to understand how current treatments work. Finasteride and dutasteride are 5-alpha-reductase inhibitors. They stop the enzyme that converts testosterone into DHT. Less DHT in the body means less hormonal attack on genetically susceptible hair follicles. The problem is that DHT does other things too. It contributes to libido, muscle mass maintenance, and prostate health. Systemically reducing DHT can produce side effects in some users.
Clascoterone takes a completely different route. Instead of reducing DHT production, it competes with DHT for binding at the androgen receptor in the skin. Think of it as blocking the lock rather than reducing the number of keys. The drug is applied topically to the scalp, where it acts locally on hair follicles without significantly lowering systemic DHT levels. This localized mechanism is why researchers believe it may offer a better safety profile than oral finasteride, particularly for patients who experience side effects or for women who cannot take oral anti-androgens.
The molecule itself, known chemically as cortexolone 17alpha-propionate, has been studied for over a decade. Its topical formulation is designed to be metabolized quickly at the application site, minimizing systemic absorption. Early pharmacokinetic data showed that even after applying the maximum recommended dose, blood levels of the active compound remained below detectable thresholds in most subjects.
Clinical Trial Results: What the Data Actually Shows
The pivotal moment for clascoterone in hair loss came in 2025, when Cosmo Pharmaceuticals announced positive results from two Phase III clinical trials evaluating a 5% topical clascoterone solution for androgenetic alopecia in men. The trials enrolled over 1,400 participants across multiple centers and ran for 12 months.
Here’s what the data showed:
- Statistically significant improvement in target area hair count compared to placebo after 12 months of twice-daily application
- Improvement was observed as early as 6 months, with continued improvement through the 12-month mark
- The safety profile was comparable to placebo, with no reports of sexual dysfunction or significant hormonal changes
- Local scalp irritation was the most common side effect, reported in a small percentage of users
Now, it’s worth putting these results in context. The hair count improvements, while statistically significant, appear to be in a similar range to what finasteride produces. Clascoterone is not a miracle cure. It’s not going to regrow a fully bald scalp. What it offers is an alternative mechanism of action for people who either can’t tolerate finasteride or prefer not to systemically alter their hormone levels.
Who Stands to Benefit Most?
Based on the clinical data and the drug’s mechanism, several groups of patients could particularly benefit from clascoterone if it receives FDA approval for hair loss:
Men who experienced finasteride side effects. This is probably the largest underserved group in hair loss treatment today. Estimates vary, but roughly 1-3% of finasteride users report persistent sexual side effects. These patients currently have limited options: topical minoxidil, low-level laser therapy, or hair transplant surgery. A topical anti-androgen that doesn’t suppress systemic DHT would fill a significant gap.
Women with female pattern hair loss. Oral finasteride is generally contraindicated in women of childbearing potential due to the risk of male fetus abnormalities. Topical formulations exist but carry less robust evidence. Clascoterone’s localized action and low systemic absorption could make it a viable option for women, pending specific clinical data in female populations.
Patients who want to combine treatments. Because clascoterone works through a different mechanism than finasteride or minoxidil, it may be possible to use them in combination for additive effect. This approach, called multi-modal therapy, is already common in hair loss management. A topical androgen receptor blocker plus a 5-alpha-reductase inhibitor plus a growth stimulant could theoretically target multiple points in the hair loss cascade simultaneously.
Patients with mild to moderate loss. Like all hair loss treatments, clascoterone works best when follicles are still active. Once a follicle has completely miniaturized and stopped producing visible hair, no topical treatment is likely to revive it. Early intervention remains the single most important factor in treatment success.
Timeline: When Will It Be Available?
This is where expectations need to be managed carefully. As of mid-2026, the Phase III trial data is promising but the drug has not yet received FDA approval for the androgenetic alopecia indication. The regulatory submission process typically takes 12-18 months after Phase III data is finalized. Realistically, if approval is granted, the product could reach the market in late 2026 or 2027.
Even after approval, there are practical questions that won’t be answered immediately. What will it cost? Will insurance cover it? How will it compare in real-world effectiveness to the trial results? How will physicians integrate it into existing treatment protocols? These are the kinds of questions that only get answered after a drug has been on the market for a while.
In the meantime, the existing evidence-based options remain effective for most people. Minoxidil, available over the counter in 2% and 5% formulations, remains the first-line topical treatment. Finasteride, despite its side effect profile, has decades of data supporting its use. Low-level laser therapy devices have FDA clearance and reasonable evidence. And for those who qualify, hair transplant surgery offers the most permanent solution.
How Clascoterone Compares to Existing Treatments
To put clascoterone in perspective, here’s a brief comparison with the major established treatments:
| Treatment | Mechanism | Systemic Exposure | Key Limitation |
|---|---|---|---|
| Oral Finasteride | 5-alpha-reductase inhibitor | High (systemic DHT reduction) | Risk of sexual side effects |
| Topical Minoxidil | Growth stimulant (potassium channel opener) | Low | Doesn’t address DHT; shedding phase |
| Topical Spironolactone | Androgen receptor antagonist | Low to moderate | Limited clinical trial data for hair |
| Ketoconazole Shampoo | Mild anti-androgen + antifungal | Minimal | Adjunctive use only; modest effect |
| Clascoterone (pending) | Androgen receptor antagonist (topical) | Very low (rapid local metabolism) | Not yet approved; cost unknown |
Notice that clascoterone and topical spironolactone share the same mechanism class. The difference is that clascoterone has gone through rigorous Phase III testing specifically for hair loss, while topical spironolactone has primarily been studied in acne and off-label use. That matters from an evidence-based medicine perspective.
What to Do While You Wait
If clascoterone sounds like it might be right for you but you’re years away from being able to fill a prescription, here are some concrete steps to take now:
- Get a proper diagnosis. Not all hair loss is androgenetic. Telogen effluvium, alopecia areata, and traction alopecia require entirely different approaches. A dermatologist can perform a trichoscopy or scalp biopsy to confirm what you’re dealing with.
- Start with proven treatments. If you have androgenetic alopecia and aren’t using minoxidil, start there. It’s the lowest barrier-to-entry treatment with the broadest evidence base. If you’re a male candidate for finasteride and comfortable with the risk profile, it remains the most effective single medication.
- Optimize your scalp environment. A healthy scalp gives any topical treatment a better chance of working. This means managing conditions like seborrheic dermatitis with appropriate shampoo, avoiding harsh chemical treatments, and maintaining adequate levels of vitamins and minerals that support follicle function.
- Track your baseline. Take photos of your scalp from consistent angles and lighting every three months. When new treatments become available, you and your doctor will want to know what your starting point looked like.
- Stay informed. Clinical trial registries like ClinicalTrials.gov publish ongoing study results. Following the clascoterone development pipeline can give you early signals about efficacy in female patients, combination therapy data, and regulatory milestones.
A Reasonable Outlook
The development of clascoterone for hair loss is genuinely exciting because it represents the first new pharmacological mechanism to reach late-stage clinical trials in this space since finasteride was approved in 1997. That’s nearly three decades of relying on essentially the same two drugs. The fact that a new option is working through a different pathway, with a potentially better safety profile, is good news for everyone, regardless of whether you personally end up using it.
But excitement should be tempered with patience. Clinical trials are controlled environments. Real-world effectiveness, tolerability, and cost will only become clear after the product launches and accumulates post-market data. The smartest thing you can do right now is maintain the best possible foundation for hair health, so that when new options do become available, you’re in a position to benefit from them.
Disclaimer: Clascoterone for androgenetic alopecia has not yet received FDA approval as of the date of this article. This information is based on published clinical trial data and is for educational purposes only. Consult with a qualified healthcare provider for personalized treatment recommendations.